



Treatment Modalities for Non-small Cell Lung Cancer—A Clinical Survey

Guest Editor:

Dr. Joerg Lindenmann

Division of Thoracic and
Hyperbaric Surgery, Department
of Surgery, Medical University of
Graz, 8036 Graz, Austria

Deadline for manuscript
submissions:

closed (14 September 2023)

Message from the Guest Editor

Dear Colleagues,

Lung cancer is one of the most aggressive types of cancer, with non-small-cell lung cancer being the most common histologic subtype of primary lung cancer. Despite continuous progress in surgery, chemotherapy, radiation therapy, and immune and targeted therapies, the prognosis of non-small-cell lung cancer patients still remains modest, especially those with advanced tumor disease. For this reason, this Special Issue of *Cancers* will highlight the different surgical and non-surgical treatment modalities available for non-small-cell lung cancer, focusing on the clinical aspect and related research activity. In this context, special attention will be paid to the current multimodal treatment options, to the impact of oncological immunology, and to the role of the tumor microenvironment in order to provide a comprehensive overview of this challenging topic.

Dr. Joerg Lindenmann

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)